Is Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Aurinia Pharmaceuticals Inc. at current levels.
LUPKYNIS is a real cash-generating asset, aritinercept is the free option, and the market is paying for neither.
Where AUPH is headed
Aurinia in 2028 looks like a company the market currently refuses to underwrite. LUPKYNIS, the only approved oral therapy for lupus nephritis, is on a trajectory to clear $400M in annual sales as nephrologist adoption deepens past the early-adopter cohort and Otsuka's ex-US commercialization in Europe and Japan adds a royalty stream that drops almost entirely to the bottom line. Operating margins above 50%, $125M in free cash flow today, net cash on the balance sheet, and a buyback authorization that has already shrunk the share count meaningfully. That is the boring half of the story.
Read the full Compass Direction on AUPH
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $15.78).
See the full AUPH analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Aurinia Pharmaceuticals Inc. at current levels. LUPKYNIS is a real cash-generating asset, aritinercept is the free option, and the market is paying for neither.
What is AUPH's Compass Score?
Aurinia Pharmaceuticals Inc. scores 86/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for AUPH?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the AUPH page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.